Ahead of merg­er with Pfiz­er's gener­ic unit, My­lan makes $757M+ pur­chase for Eu­ro­pean throm­bo­sis port­fo­lio

My­lan is in­creas­ing its pres­ence in Eu­rope with a high-dol­lar ac­qui­si­tion of a blood clot port­fo­lio.

The gener­ic drug­mak­er is pay­ing more than three-quar­ters of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER